NCP-112 is under clinical development by NovaCell Technology and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NCP-112’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NCP-112 overview
NCP-112 is under development for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, dry eye, asthma, rheumatoid arthritis and symptomatic asthma of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered by topical route. It is a heptameric peptide. It acts by targeting N-Formyl Peptide Receptor 2(FPR2). The drug candidate is being developed based on peptide library technology.
NovaCell Technology overview
NovaCell Technology (NovaCell) is a pharmaceutical company which focuses on peptide technology which focuses on target analysis and new drug derivation technology. NovaCell is headquartered in Pohang, Korea.
For a complete picture of NCP-112’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
